Mental Health Education
While 'effective treatment' may bring improvements in mental health care slowly, 'Mental Health Education' can act quickly, in improving certain aspect of Mental Health Care. In this era of Information Technology, knowledge can be quickly disseminated over large geographical area, cutting across socioeconomic, linguistic and cultural barriers through media like radio, newspapers,magazines, TVS internet.
These resources are not yet tapped adequately by Mental Health Care givers or by the government. In fact, adverse and inaccurate depictions of mental illness and its treatment go unchecked in the mass media like cinemas (Wilson etal., 1999) . There has to be a focussed effort to make available credible scientific information about mental illness and its treatment, in simple language understandable to a common man (Clare, 2000) .
These two efforts, effective treatment and mental health education, will take the Mental Health Care to a greater height, than shortterm knee jerk reactions. And the onus, in these areas, lies with us, the mental health care providers. (Sethi,2001 ) I want to contribute that I reported a case of Rabbit syndrome which occurred twice in two different admissions while she received highpotency antipsychotics for just one week, the response to shift on low potency and adding antiparkinson medicines was as good as in her case (Jain, 1993) I will like to know from the author, if extrpyramidal side effects also developed on the same day the perioral movements were noted ? Extrapyramidal side effects are usually visible after one or two days of antipsychotic administration. It looks that perioral movements were noted after a week of initiation of treatment and then only antiparkinson agents were started which mean that EPS also occurred on seventh day.
SERTRALINE AND BUSPIRONE IN ADOLESCENT DELUSIONAL BODY DYSMORPHIC DISORDER

Sir,
Delusional body dysmorphic disorder (BDD) is currently known to respond well to serotonin reuptake inhibitors (SRIs). However, patients with this disorder show a variable response to this class of drugs. We report a case of pimozide-resistant delusional BDD who failed a subsequent trial of clomipramine but ultimately responded to a combination of sertraline and buspirone.
U.K., a 14-year-old girl, had been suffering for about 6 months from the belief that her eyes were becoming smaller and that her lower lip was smaller than her upper lip. The patient was deeply convinced about this belief, would spend an hour each day examining her face in front of a mirror and would apply lipstick to conceal the imagined defect. However, this behavior was never ego dystonic and she had no insight in to the psychological nature of her illness. She avoided meeting people, stopped going to the school, remained sad and expressed loss of interest, hopelessness, worthless and demonstrated vegetative signs suggestive of a mild depressive episode. During the entire illness, she never had obsessive-compulsive symptoms qualifying for a disorder. Family history was positive for paranoid schizophrenia in father but there was no history of any obsessive-compulsive spectrum disorder.
The patient was diagnosed with delusional BDD and treated with pimozide up to 4 mg/day, which was discontinued after 5 months in view of severe extrapyramidal symptoms and no apparent improvement in her beliefs. Subsequently, she was treated with clomipramine up to 200 mg/day for 3 months. Her depressive symptoms improved but her beliefs on the imagined defect persisted with the same intensity. Therefore, buspirone was added for augmentation. At a dose of 200 mg/day of clomipramine and 15 mg/day of buspirone, the patient had two episodes of generalized seizures. An EEG and cranial CT scan did not reveal any abnormality to suggest focal brain pathology. Clomipramine, due to its seizurogenic potential, was replaced with sertraline, which was increased to 150 mg/day while buspirone was continued at 15 mg/day. Within two months of commencing this combination, the patient started showing improvement. Her frequency of mirror gazing decreased and she became more social. In another two months, she had rid herself of the delusional beliefs and was back to school. Currently, she is asymptomatic on this regimen for the past two years.
To our knowledge, this is the first adolescent case of BDD where a combination of clomipramine and buspirone and sertraline and buspirone were tried in the same patient. Similar reports in adults have been documented in literature (Guggenheim, 2000) while the safety and efficacy of sertraline alone in adolescent BDD has been shown only anecdotally (Ei-khatib & Dickey, 1995) . In addition, this case offers other interesting
